Atara Biotherapeutics (ATRA) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free ATRA Stock Alerts $0.61 -0.01 (-1.96%) (As of 02:33 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 27 at 1:20 AM | americanbankingnews.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Hold" by BrokeragesMay 25 at 1:42 AM | americanbankingnews.comAtara Biotherapeutics, Inc. to Post Q2 2024 Earnings of $0.06 Per Share, HC Wainwright Forecasts (NASDAQ:ATRA)May 24, 2024 | marketbeat.comQ2 2024 EPS Estimates for Atara Biotherapeutics, Inc. Boosted by Analyst (NASDAQ:ATRA)Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) - Stock analysts at HC Wainwright upped their Q2 2024 earnings per share estimates for shares of Atara Biotherapeutics in a research report issued to clients and investors on Wednesday, May 22nd. HC Wainwright analyst R. Burns now anticipateMay 24, 2024 | americanbankingnews.comHC Wainwright Weighs in on Atara Biotherapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ATRA)May 23, 2024 | marketbeat.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Expected to Post Q1 2025 Earnings of ($0.27) Per ShareAtara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Atara Biotherapeutics in a research note issued on Wednesday, May 22nd. HC Wainwright analyst R. Burns expects that the biotechnology company wMay 23, 2024 | americanbankingnews.comAtara Biotherapeutics (NASDAQ:ATRA) Given Neutral Rating at HC WainwrightMay 22, 2024 | marketbeat.comHC Wainwright Reaffirms "Neutral" Rating for Atara Biotherapeutics (NASDAQ:ATRA)HC Wainwright reiterated a "neutral" rating on shares of Atara Biotherapeutics in a report on Wednesday.May 21, 2024 | americanbankingnews.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Anhco Nguyen Sells 42,899 SharesMay 21, 2024 | americanbankingnews.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Eric J. Hyllengren Sells 28,648 Shares of StockMay 21, 2024 | insidertrades.comEric J. Hyllengren Sells 28,648 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) StockMay 21, 2024 | insidertrades.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Pascal Touchon Sells 81,506 SharesMay 20, 2024 | marketbeat.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Eric J. Hyllengren Sells 28,648 SharesAtara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) CFO Eric J. Hyllengren sold 28,648 shares of the company's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $0.62, for a total transaction of $17,761.76. Following the completion of the sale, the chief financial officer now directly owns 645,671 shares in the company, valued at $400,316.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.May 20, 2024 | finance.yahoo.comAtara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares RiseMay 20, 2024 | businesswire.comAtara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDAMay 11, 2024 | finance.yahoo.comAtara Biotherapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Atara Biotherapeutics on Strong Pipeline and Financial HealthMay 10, 2024 | investorplace.comATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | washingtonpost.comAtara Biotherapeutics: Q1 Earnings SnapshotMay 9, 2024 | businesswire.comAtara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational ProgressMay 3, 2024 | businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 5, 2024 | businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)March 28, 2024 | investorplace.comATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023March 28, 2024 | benzinga.comAtara Biotherapeutics: Q4 Earnings InsightsMarch 28, 2024 | finance.yahoo.comAtara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational ProgressMarch 18, 2024 | marketbeat.comAtara Biotherapeutics (NASDAQ:ATRA) Lowered to Sell at StockNews.comStockNews.com downgraded Atara Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Monday.March 18, 2024 | marketbeat.comShort Interest in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Declines By 6.7%Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 29th, there was short interest totalling 10,140,000 shares, a decrease of 6.7% from the February 14th total of 10,870,000 shares. Based on an average daily trading volume, of 3,640,000 shares, the short-interest ratio is currently 2.8 days.March 16, 2024 | insidertrades.comInsider Selling: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Sells 24,844 Shares of StockMarch 16, 2024 | finance.yahoo.comATRA Apr 2024 0.500 callMarch 3, 2024 | marketbeat.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Short Interest Up 44.4% in FebruaryAtara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 10,870,000 shares, an increase of 44.4% from the January 31st total of 7,530,000 shares. Based on an average daily volume of 3,690,000 shares, the short-interest ratio is currently 2.9 days.February 29, 2024 | msn.comFDA clears Atara to begin Phase 1 study for lupus nephritis drugFebruary 29, 2024 | marketwatch.comAtara Biotherapeutics Gets FDA Clearance for ATA3219 IND ApplicationFebruary 29, 2024 | finance.yahoo.comAtara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T TherapyFebruary 28, 2024 | finance.yahoo.comAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care ConferenceFebruary 14, 2024 | finance.yahoo.comAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus NephritisFebruary 14, 2024 | businesswire.comAtara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus NephritisFebruary 9, 2024 | uk.investing.comAtara Biotherapeutics Inc (ATRA)February 6, 2024 | uk.finance.yahoo.comAtara Biotherapeutics, Inc. (0HIY.L)February 5, 2024 | seekingalpha.comAtara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer RunwayFebruary 3, 2024 | finance.yahoo.comAfter losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gainJanuary 11, 2024 | finance.yahoo.comSeth Klarman's Firm Exits Atara Biotherapeutics Inc HoldingJanuary 11, 2024 | finance.yahoo.comSeth Klarman's Exit from Atara Biotherapeutics IncJanuary 9, 2024 | businesswire.comTab-cel BLA on Track for Submission in Q2 2024 Following Positive New Data from Pivotal ALLELE StudyJanuary 8, 2024 | msn.comAtara to conduct $15M registered direct offeringJanuary 8, 2024 | finance.yahoo.comAtara Biotherapeutics Announces $15 Million Registered Direct OfferingJanuary 8, 2024 | finance.yahoo.comAtara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 4, 2024 | finance.yahoo.comAtara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 20, 2023 | finance.yahoo.comAtara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre LaboratoriesDecember 19, 2023 | msn.comAtara reportedly laying off 73 workers in wake of failed MS drug studyDecember 11, 2023 | businesswire.comNo Observed Treatment-Related Toxicities or Alloreactivity Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Digitizing the $11T commodities sector with one tiny stock (Ad)One tiny company — trading completely undiscovered around 15-cents per share — has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. It’s an opportunity that likely won’t stay at these levels for long ATRA Media Mentions By Week ATRA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRA News Sentiment▼1.020.92▲Average Medical News Sentiment ATRA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRA Articles This Week▼162▲ATRA Articles Average Week Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ELUT News CGTX News PASG News PLX News GRTS News DTIL News ALVR News TIL News CVM News ENTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATRA) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesThe only AI company to buyPorter & CompanyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestWARNING about the death of the U.S. dollar…Colonial MetalsBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
